Geneos Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Geneos Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-238	Closed	-$77.6K	–	2495
2025 Q2	$77.6K	Buy	238 +16	+7%	+$4.43K	﹤0.01%	1359
2025 Q1	$59.9K	Buy	222 +175	+372%	+$45K	﹤0.01%	1394
2024 Q4	$11.1K	Hold	47	–	–	﹤0.01%	2013
2024 Q3	$12.9K	Buy	+47	New	+$12.2K	﹤0.01%	1729
2022 Q3	–	Sell	-986	Closed	-$146K	–	2016
2022 Q2	$146K	Sell	986 -679	-41%	-$96.3K	0.01%	864
2022 Q1	$271K	Sell	1,665 -58	-3%	-$8.84K	0.01%	697
2021 Q4	$292K	Buy	1,723 +37	+2%	+$6.88K	0.01%	741
2021 Q3	$324K	Buy	1,686 +3	+0.2%	+$563	0.01%	683
2021 Q2	$288K	Sell	1,683 -103	-6%	-$15.1K	0.01%	706
2021 Q1	$251K	Sell	1,786 -224	-11%	-$33.7K	0.01%	877
2020 Q4	$276K	Buy	+2,010	New	+$268K	0.01%	714
2017 Q2	–	Sell	-24	Closed	-$1K	–	2070
2017 Q1	$1K	Sell	24 -18	-43%	-$832	﹤0.01%	1957
2016 Q4	$1K	Hold	42	–	–	﹤0.01%	1921
2016 Q3	$2K	Buy	+42	New	+$2.96K	﹤0.01%	1741

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geneos Wealth Management's ALNY Position: Q3 2025 in Review

Geneos Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 238 shares — an estimated $77.6K sold.

Geneos Wealth Management first reported a position in ALNY in Q3 2016 and held it in 14 quarters. The position peaked at $324K in Q3 2021. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Geneos Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Geneos Wealth Management sold 238 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $77.6K.
Geneos Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 14 quarters.
Geneos Wealth Management's Alnylam Pharmaceuticals position peaked at $324K in Q3 2021.
823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.